Identification of Potential Serum Proteomic Biomarkers for Clear Cell Renal Cell Carcinoma

Abstract

ObjectiveTo investigate discriminating protein patterns and serum biomarkers between clear cell renal cell carcinoma (ccRCC) patients and healthy controls, as well as between paired pre- and post-operative ccRCC patients.MethodsWe used magnetic bead-based separation followed by matrix-assisted laser desorption ionization (MALDI) time-of-flight (TOF) mass spectrometry (MS) to identify patients with ccRCC. A total of 162 serum samples were analyzed in this study, among which there were 58 serum samples from ccRCC patients, 40 from additional paired pre- and post-operative ccRCC patients (n = 20), and 64 from healthy volunteers as healthy controls. ClinProTools software identified several distinct markers between ccRCC patients and healthy controls, as well as between pre- and post-operative patients.ResultsPatients with ccRCC could be identified with a mean sensitivity of 88.38% and a mean specificity of 91.67%. Of 67 m/z peaks that differed among the ccRCC, healthy controls, pre- and post-operative ccRCC patients, 24 were significantly different (P<0.05). Three candidate peaks, which were upregulated in ccRCC group and showed a tendency to return to healthy control values after surgery, were identified as peptide regions of RNA-binding protein 6 (RBP6), tubulin beta chain (TUBB), and zinc finger protein 3 (ZFP3) with the m/z values of 1466.98, 1618.22, and 5905.23, respectively.ConclusionMB-MALDI-TOF-MS method could generate serum peptidome profiles of ccRCC, and provide a new approach to identify potential biomarkers for diagnosis as well as prognosis of this malignancy.

Development and validation of a 4-gene combination for the prognostication in lung adenocarcinoma patients

“…ZFP3 contains a conserved structural motif that mediates its binding to protein, DNA and RNA, in humans ZFP3 has been localized to chromosome 17p12-17pter [46]. Ming et al reported that the ZFP3 had protective effect in clear cell renal cell carcinoma [47], which was consistent with our research.…”

Challenges and Opportunities in Clinical Applications of Blood-Based Proteomics in Cancer

“…Mammography is one of the most important screening tools as a population strategy, but has limitations in young women (under 40 years old) or women with large breasts, with a sensitivity of as low as 25–59% and high rates of false negative and false positive in diagnosis [ 170 ]. Blood-based proteomics as a screening diagnostic with novel noninvasive biomarkers for the early detection of BCa in asymptomatic individuals for the diagnosis and prognosis of the disease states has been an area of research interest [ 171 , 172 ]. Promising candidate biomarkers such as CA125, carcinoembryonic antigen (CEA), oncogenic protein RS/DJ-1, human epidermal growth factor receptor-2 (HER2), and circulating cytokeratin fragments (tissue polypeptide antigen (TPA), tissue polypeptide-specific antigen (TPS), and CYFRA 21-1) have been identified, but are pending validation [ 173 ].…”

Identification of Biomarkers for Endometriosis Using Clinical Proteomics

“…When we used ClinProtools Software (Bruker Daltonics) to search for differential proteins and design models,[ 10 ] we found that not only the number, mass of candidate proteins, but also the potential importance of these proteins; that is, candidate proteins with lower peak intensities appeared to be less meaningful in this context. We, therefore, tried to improve the analytic process.…”